MARKET DYNAMICS

MARKET DRIVERS

Expansion of Minimally Invasive and Robotic Surgery Drives Insufflator Demand

The surge in minimally invasive procedures has become the principal catalyst for the insufflator market. Global estimates indicate that more than 15 million laparoscopic surgeries were performed in 2023, representing a compound annual increase of roughly 12 % since 2018, while robot‑assisted operations surpassed 2.5 million cases in the same year, growing at an annual rate of about 20 %. Each of these procedures relies on a reliable source of carbon‑dioxide to establish a stable pneumoperitoneum, making the insufflator an indispensable component of the surgical ecosystem. The resulting demand translates directly into market revenue: the global insufflator market was valued at US$ 301 million in 2025 and is projected to reach US$ 504 million by 2034, reflecting a CAGR of 7.6 % over the forecast horizon. Hospital networks in North America and Europe, where the penetration of laparoscopic and robotic platforms is already high, are continually upgrading legacy devices to meet modern safety and performance standards. Simultaneously, emerging economies in Asia‑Pacific are rapidly expanding their surgical infrastructure, with a 30 % increase in newly built minimally invasive surgery centers expected between 2024 and 2029. This expansion fuels a steady rise in the annual global sales volume, which reached approximately 60 000 units in 2025, and underlines the enduring relevance of insufflators across all surgical specialties.

Technological Advancements in Intelligent Flow‑Control and Gas Conditioning

Innovation in insufflator technology is reshaping the value proposition for healthcare providers. Modern devices now incorporate intelligent feedback control loops that continuously monitor intra‑abdominal pressure, gas flow, and temperature, automatically adjusting parameters to maintain a low‑pressure, high‑flow environment. These systems have demonstrated a reduction in CO₂ consumption of up to 15 %, delivering cost savings that directly improve the gross profit margin currently estimated at 50 % for manufacturers. Advanced heating and humidification modules mitigate the physiological irritation caused by dry, cold gas, decreasing postoperative pain scores and shortening hospital stays by an average of 0.8 days per case. Market segmentation data reveal that intelligent feedback control insufflators command roughly 45 % of the total market share in 2025, while high‑flow models account for about 35 %, reflecting strong clinician preference for devices that enhance procedural efficiency and patient comfort. The convergence of AI‑driven analytics, IoT connectivity, and modular design enables seamless integration with laparoscopic towers, imaging systems, and robotic platforms, further differentiating premium offerings and driving incremental revenue growth.

Rising Healthcare Infrastructure Investment in Emerging Asia‑Pacific Markets

Capital investment in healthcare infrastructure across the Asia‑Pacific region is accelerating at an unprecedented pace, creating a fertile environment for insufflator adoption. Between 2022 and 2027, the region is projected to witness a combined annual growth rate of 18 % in the construction of new surgical suites equipped for laparoscopy and robot‑assisted procedures. China alone accounted for more than 30 % of global laparoscopic case volume in 2023, while India’s minimally invasive surgery market expanded by roughly 22 % year‑over‑year, driven by government‑backed initiatives to upgrade tertiary hospitals. These developments are complemented by a rising average selling price of US$ 5 500 per unit in 2025, reflecting the premium placed on intelligent, low‑pressure systems that align with modern peri‑operative standards. Moreover, the growing prevalence of obesity and related comorbidities is fueling demand for bariatric interventions, a segment where insufflators are essential for safe abdominal access. The cumulative effect of expanding clinical capacity, favorable reimbursement policies, and a demographic shift toward surgical solutions for chronic diseases is expected to sustain robust demand for both new installations and replacement cycles, reinforcing the market’s projected trajectory toward US$ 504 million by 2034.

Regulatory Support for Standardized Pneumoperitoneum Safety Guidelines

Regulatory agencies worldwide are strengthening guidelines that directly impact insufflator design and procurement. Recent updates to the U.S. FDA’s safety recommendations for laparoscopic equipment emphasize automated pressure alarms, real‑time monitoring, and fail‑safe shut‑off mechanisms. In parallel, the European Union’s Medical Device Regulation (MDR) mandates conformity with IEC 60601‑2‑40 standards for surgical evacuation and insufflation systems, requiring manufacturers to validate performance across a broader range of clinical scenarios. These regulatory enhancements incentivize hospitals to retire older, non‑compliant models in favor of next‑generation insufflators that embed advanced safety features. As compliance becomes a prerequisite for credentialing and insurance reimbursement, procurement cycles are increasingly driven by the need to align with updated standards, propelling demand for devices that combine intelligent control, gas conditioning, and comprehensive alarm systems. The regulatory momentum thus reinforces market growth, ensuring that the projected CAGR of 7.6 % remains underpinned by a clear mandate for safety and performance excellence.

MARKET CHALLENGES

High Capital Expenditure for Advanced Insufflator Systems Limits Adoption in Price‑Sensitive Hospitals

While the clinical advantages of intelligent insufflators are well documented, the upfront investment required to acquire these systems poses a significant barrier, particularly for community hospitals and clinics operating under constrained budgets. Premium models equipped with real‑time pressure feedback, automated flow regulation, and integrated heating/humidification typically retail between US$ 8 000 and US$ 12 000, substantially higher than the average selling price of US$ 5 500 for standard units. When amortized over a typical equipment lifecycle of five to seven years, the annualized cost can consume a sizeable portion of operating budgets, limiting capital allocation for other essential services. This price sensitivity is especially pronounced in emerging markets where per‑procedure reimbursement rates remain modest. Consequently, many institutions defer the transition to advanced insufflators, opting instead for lower‑cost legacy devices that lack modern safety and efficiency features. The resulting delay in technology refresh cycles curtails market momentum, creating a lag between clinical demand for superior performance and actual purchase behavior.

Other Challenges

Regulatory Hurdles

The path to market entry for next‑generation insufflators is increasingly encumbered by rigorous regulatory scrutiny. In the European Union, the MDR requires extensive clinical evidence to demonstrate compliance with new safety and performance criteria, extending the time‑to‑market by an average of 12‑18 months compared with prior directives. Similarly, the FDA’s 510(k) clearance process now mandates detailed testing of intelligent control algorithms and gas‑conditioning modules, elevating development costs and resource allocation. These heightened requirements not only inflate the cost structure but also introduce uncertainty regarding approval timelines, discouraging some manufacturers from pursuing innovative features that could otherwise differentiate their product lines. For smaller players lacking extensive regulatory expertise, the hurdle becomes even more prohibitive, consolidating market share among the few large, well‑resourced companies.

Skill Shortage and Training Complexity

The sophisticated functionality embedded in modern insufflators demands a higher level of technical proficiency from operating room staff, biomedical engineers, and clinical educators. Advanced devices featuring AI‑driven flow optimization, remote diagnostics, and modular interfaces require comprehensive training programs to ensure safe and effective use. However, a global shortage of qualified biomedical technicians exacerbated by an aging workforce and limited pipeline of specialized graduates hampers the ability of hospitals to fully exploit these capabilities. Training initiatives are often fragmented, with manufacturers providing inconsistent curricula across regions, leading to variable competency levels. This skill gap translates into slower adoption rates, as institutions may postpone procurement until they can guarantee adequate personnel support, thereby imposing an additional restraint on market expansion.

MARKET RESTRAINTS

Technical Integration Issues and Interoperability with Robotic Platforms

The rapid proliferation of robotic surgical systems has introduced complex integration challenges for insufflator manufacturers. Different robotic platforms such as the da Vinci, Versius, and Senhance utilize proprietary communication protocols and mechanical interfaces, making seamless connection with insufflation units a non‑trivial engineering task. In many cases, custom adapters or middleware are required to synchronize pressure settings and flow rates with robot‑controlled instrument movements, resulting in additional hardware costs and extended installation times. These interoperability obstacles can deter hospitals from adopting a unified, vendor‑agnostic solution, compelling them to select insufflators that are only compatible with a single robotic system. The resulting fragmentation limits economies of scale, inflates total cost of ownership, and slows the overall market momentum toward a fully integrated, robot‑ready operating suite.

The need for rigorous validation of integrated systems also adds to the restraint. Each new combination of robot and insufflator must undergo extensive verification to meet safety standards, including tests for pressure latency, alarm response times, and fail‑safe mechanisms. This validation process can take several months per configuration, delaying rollout schedules and discouraging hospitals from pursuing upgrades that involve multiple technology stacks. As a result, the market experiences a bottleneck where advanced devices are technically available but remain under‑utilized due to the practical complexities of achieving a fully interoperable surgical environment.

Furthermore, legacy infrastructure in many established hospitals such as older laparoscopic towers and hospital information systems lacks the digital interfaces required to support next‑generation, network‑enabled insufflators. Upgrading these ancillary components often entails significant capital outlay and lengthy procurement cycles, creating a secondary layer of restraint that compounds the challenges associated with direct device integration. This systemic inertia contributes to a slower diffusion of intelligent insufflation technology, particularly in regions where capital investment cycles are already extended.

MARKET OPPORTUNITIES

Surge in Strategic Partnerships and Product Innovation by Key Players

Key manufacturers are actively forging strategic alliances to accelerate the development of next‑generation insufflation solutions. Collaborative projects between insufflator producers and AI‑analytics firms are yielding platforms that predict optimal flow rates based on patient‑specific anatomy, thereby enhancing safety margins and reducing intra‑operative complications. Simultaneously, joint ventures with leading imaging companies are enabling tightly coupled insufflator‑endoscope systems that share real‑time pressure data with high‑definition visual feeds, facilitating automated adjustments that maintain a consistent surgical field. These partnerships not only broaden the functional envelope of insufflators but also create cross‑selling opportunities within established product portfolios, driving incremental revenue streams. Market analysts anticipate that such collaborative innovations could capture an additional 12‑15 % of the total market share by 2030, especially as hospitals seek bundled solutions that streamline procurement and simplify staff training.

Another emerging opportunity lies in the growing demand for single‑use, disposable insufflation devices. Infection control concerns accentuated by recent global health events have prompted many healthcare facilities to evaluate disposable alternatives that eliminate the need for reprocessing and reduce the risk of cross‑contamination. Early adopters report a reduction in turnaround time of up to 30 %, translating into higher operating room efficiency. Industry forecasts suggest that disposable insufflators could account for approximately 12 % of global unit shipments by 2034, offering manufacturers a profitable niche with higher gross margins due to the consumable nature of the product.

Finally, the expansion of minimally invasive surgery centers in emerging economies presents a fertile ground for market growth. Governments across Southeast Asia and Latin America are implementing policies that subsidize the acquisition of advanced surgical equipment to improve population health outcomes. Coupled with rising private‑sector investment in diagnostic and therapeutic facilities, these initiatives are poised to generate a substantial increase in demand for intelligent, cost‑effective insufflation systems. Companies that tailor product configurations to meet the price sensitivities and regulatory environments of these markets such as offering modular, upgradeable platforms stand to benefit from a sizable untapped patient base, reinforcing the long‑term upside potential of the insufflator market.

The global Insufflator market was valued at US$ 301 million in 2025 and is projected to reach US$ 504 million by 2034, at a CAGR of 7.6% during the forecast period.

Segment Analysis:

By Type

High‑Flow Insufflator Segment Leads the Market Driven by Robotic‑Assisted Surgery Demands

The market is segmented based on type into:

• High Flow Insufflator

• Middle Flow Insufflator

• Low Flow Insufflator

• Intelligent Feedback Control Insufflator

• Manual‑Control Insufflator

By Application

Laparoscopy Application Segment Dominates Due to Widespread Adoption in Minimally Invasive Procedures

The market is segmented based on application into:

• Laparoscopy

• Bariatric Surgery

• Heart Surgery

• Other Surgery

By End User

Hospitals Segment Leads Adoption Owing to High‑Volume Surgical Programs

The market is segmented based on end user into:

• Hospitals

• Ambulatory Surgical Centers

• Research Institutions

• Veterinary Clinics

• Others

COMPETITIVE LANDSCAPE

Key Industry Players

Companies Strive to Strengthen their Product Portfolio to Sustain Competition

The global Insufflator market was valued at USD 301 million in 2025 and is projected to reach USD 504 million by 2034, expanding at a CAGR of 7.6 % during the forecast period. Insufflators are essential for creating a stable pneumoperitoneum in laparoscopic, gynecologic, urologic, thoracic and robotic‑assisted surgeries. Their core functions CO₂ delivery, pressure control, flow regulation, heating and humidification, and real‑time monitoring have driven demand for high‑flow, intelligent, low‑pressure solutions, especially as hospitals worldwide invest in minimally invasive surgical suites.

The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size manufacturers. W.O.M. leads the segment, leveraging a broad portfolio that includes high‑flow and intelligent feedback control systems, and a strong presence in North America and Europe. Stryker and Karl Storz hold significant shares in 2024, propelled by rapid adoption of robot‑compatible devices and strategic partnerships with surgical platform providers.

Meanwhile, Richard Wolf, Olympus and B. Braun have expanded their market footprint through the introduction of modular insufflator platforms that integrate gas heating and humidification, addressing postoperative pain concerns. Their growth initiatives geographic expansion into emerging Asia‑Pacific markets and launch of next‑generation low‑pressure units are expected to raise their share considerably over the next decade.

In addition, Hoya, STERIS, Fujifilm and Smith & Nephew are reinforcing their positions by investing in R&D, forming strategic alliances with robotic surgery manufacturers, and delivering intelligent, cloud‑connected insufflation solutions that meet the evolving expectations of modern operating rooms.

List of Key Insufflator Companies Profiled

• W.O.M.

• Stryker

• Karl Storz

• Richard Wolf

• Olympus

• B. Braun

• Hoya

• STERIS

• Fujifilm

• Smith & Nephew

• Bracco

• CONMED

• Northgate Technologies

• Shiyin Medical

• Arthrex

• GIMMI GmbH

• Hawk

• Tonglu Jingrui

• Kangyou Medical

DNA MODIFYING ENZYMES MARKET TRENDS

Advancements in Minimally Invasive Surgery Technologies to Emerge as a Trend in the Market

The global Insufflator market was valued at US$ 301 million in 2025 and is projected to reach US$ 504 million by 2034, growing at a CAGR of 7.6 % during the forecast period. An insufflator is a critical device that continuously delivers carbon dioxide (CO₂) into the patient’s abdominal cavity, establishing a stable pneumoperitoneum that furnishes surgeons with adequate working space and a clear visual field. Modern insufflators integrate a gas‑pressure control module, precise flow‑regulation, heating and humidification units, real‑time monitoring displays, and safety alarms, allowing automatic adjustment of pressure and flow to safeguard patient safety. Carbon dioxide remains the preferred working gas due to its non‑flammability, rapid absorption, and minimal physiological irritation. These devices are indispensable across general surgery, gynecology, urology, thoracic procedures, and robot‑assisted surgeries, often interfacing with laparoscopes, high‑definition imaging systems, and energy devices.

Other Trends

Robotic‑Assisted Surgery Integration

Accelerating adoption of robotic platforms is reshaping insufflator demand. Hospitals are opting for high‑flow, intelligent insufflators that can synchronize with robotic consoles, delivering low‑pressure, stable pneumoperitoneum while minimizing tissue trauma. In 2025 the average selling price of an insufflator was approximately US$ 5,500 per unit, with global sales volume reaching around 60,000 units. Manufacturers enjoy an average gross profit margin of about 50 %, reflecting strong pricing power driven by advanced features such as automatic flow regulation, real‑time pressure feedback, and digital integration. As robotic‑assisted procedures expand beyond urology and gynecology into complex colorectal and cardiothoracic surgeries, the market will witness heightened demand for devices that support seamless data exchange, remote monitoring, and predictive maintenance.

Technological Innovations in Insufflation Systems

Future insufflators are evolving toward comprehensive thermal and humidity management to mitigate postoperative pain and peritoneal desiccation. New generations incorporate gas‑heating and humidification modules that deliver CO₂ at body‑temperature and optimal moisture levels, preserving peritoneal integrity and reducing inflammatory response. Intelligent feedback control algorithms, powered by AI, continuously analyze intra‑abdominal pressure trends and adjust flow rates, ensuring a consistently stable environment even during dynamic surgical maneuvers. Moreover, modular and cart‑based designs are gaining traction, offering scalability and easier integration with operating‑room digital ecosystems. Hospital infrastructure development, especially in emerging Asia‑Pacific markets, coupled with the proliferation of minimally invasive surgical centers, will further fuel demand for these high‑end, robot‑compatible insufflators, reinforcing the market’s trajectory toward sophisticated, patient‑centric solutions.

Regional Analysis

Which region accounts for the largest share of the global Insufflator market?

North America currently holds the largest share of the global Insufflator market. In 2025 the region contributed roughly 35 % of the total market value, driven by a mature healthcare infrastructure, extensive adoption of robotic‑assisted laparoscopic procedures, and strong purchasing power of hospitals in the United States and Canada. The United States alone accounts for more than half of the regional revenue, thanks to the concentration of leading academic medical centers, a high density of ambulatory surgery facilities, and early adoption of intelligent, high‑flow insufflation systems. Robust reimbursement frameworks and ongoing investments in minimally invasive surgery (MIS) training programs further cement North America’s leadership position.

Key Highlights:

• Advanced adoption of high‑flow, intelligent insufflators in major teaching hospitals
• Strong reimbursement policies supporting MIS and robotic surgery
• Presence of leading manufacturers such as Stryker, Olympus, and Richard Wolf with dedicated North American R&D hubs
• Continued capital expenditure for operating‑room upgrades in the post‑COVID recovery phase
• Growing demand for gas‑heating and humidification modules to improve patient outcomes

Which region is projected to witness the fastest growth in the Insufflator market during 2026–2034?

Asia‑Pacific is projected to be the fastest‑growing region over the 2026–2034 forecast horizon, with an expected compound annual growth rate (CAGR) of about 9 % well above the global average of 7.6 %. The surge is propelled by rapid urbanization, expanding tertiary‑care networks, and aggressive rollout of robotic surgery platforms in China, Japan, South Korea, and India. Government‑backed initiatives to modernize public hospitals, coupled with rising private‑equity investment in specialty surgery centers, are accelerating demand for next‑generation insufflators. Moreover, the region’s large patient base and increasing prevalence of obesity and related bariatric procedures create a fertile market for high‑flow, low‑pressure devices.

Key Highlights:

• Accelerated adoption of robotic platforms such as Da Vinci and Mako in major Asian metros
• Large‑scale public‑hospital modernization programs targeting MIS capabilities
• Growing middle‑class population driving elective surgery volumes
• Strategic partnerships between local distributors and global OEMs to localize intelligent insufflator technology
• Increasing regulatory approvals for advanced gas‑heating and humidification features

How is the expansion of minimally invasive and robotic surgery influencing regional demand for Insufflators?

The worldwide expansion of minimally invasive and robotic‑assisted procedures is a primary catalyst reshaping regional demand for insufflators. As surgeons transition from conventional laparoscopy to high‑precision robotic systems, the need for stable pneumoperitoneum, rapid gas flow, and precise pressure feedback becomes critical. Consequently, regions with high robotic‑surgery penetration namely North America, Europe, and increasingly Asia‑Pacific are upgrading legacy insufflation units to intelligent, low‑pressure models that integrate seamlessly with surgical consoles. The push for patient‑centered outcomes, such as reduced postoperative pain through gas humidification, further intensifies demand for premium devices.

Key Highlights:

• Robotic platforms require low‑pressure, high‑flow insufflation to maintain camera stability
• Intelligent feedback control units reduce intra‑operative complications, driving adoption in safety‑focused markets
• Hospital procurement committees favor devices offering real‑time pressure analytics and alarm systems
• Emergence of modular insufflator designs that can be retrofitted to existing robotic carts
• Increasing preference for disposable, single‑use flow regulators in high‑throughput ambulatory centers

Which countries are emerging as key investment hubs for Insufflator solutions?

Key investment hubs include the United States, China, India, Germany, Japan, and Saudi Arabia. In the United States, capital spending on operating‑room upgrades continues to exceed $2 billion annually, with a sizable portion earmarked for advanced insufflation technology. China’s “Healthy China 2030” plan earmarks over $10 billion for hospital modernization, creating a large pipeline for both high‑flow and intelligent devices. India’s rapid growth of private surgical centers and the government’s focus on expanding laparoscopic services make it a fertile market. Germany and Japan, with their strong regulatory environments and emphasis on precision surgery, attract high‑margin investments from OEMs seeking to launch premium, humidity‑controlled units. Saudi Arabia’s Vision 2030 health‑care diversification program also funds the establishment of state‑of‑the‑art surgical suites across the Kingdom.

Key Highlights:

• Significant public‑private partnerships funding MIS suites in emerging economies
• Local manufacturing incentives in China and India encouraging joint‑venture models
• High willingness to pay for intelligent, data‑connected insufflators in Germany and Japan
• Strategic hospital networks in the Gulf region prioritizing robotic‑compatible equipment
• Growing demand for disposable accessories to meet infection‑control standards

How are smart hospital initiatives and infrastructure modernization projects impacting regional market growth?

Smart hospital initiatives characterized by integrated digital operating rooms, IoT‑enabled equipment monitoring, and data‑driven workflow optimization are accelerating insufflator market penetration across all regions. In North America, major academic centers are deploying fully connected surgical suites where insufflators communicate real‑time pressure data to central analytics platforms, enabling predictive maintenance and enhanced patient safety. European hospitals are retrofitting legacy operating rooms with modular insufflation systems that support both laparoscopic and robotic procedures, aligning with sustainability goals to reduce energy consumption. In Asia‑Pacific, large‑scale infrastructure projects, such as the construction of new tertiary hospitals in tier‑1 cities, embed intelligent insufflation technology as a baseline requirement, spurred by national policies promoting minimally invasive surgery. These modernization efforts collectively drive higher adoption rates, longer device lifecycles, and increased demand for service contracts.

Key Highlights:

• Integration of insufflator telemetry into hospital IT ecosystems for real‑time quality control
• Adoption of gas‑heating and humidification modules to meet enhanced recovery after surgery (ERAS) protocols
• Growth of subscription‑based service models tied to device performance analytics
• Regulatory encouragement for low‑pressure, patient‑comfort‑focused technologies in Europe and North America
• Expansion of training programs on intelligent insufflation across emerging markets to ensure clinical proficiency

Insufflator Market

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• ✅ Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• ✅ Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• ✅ Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• ✅ Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&A, partnerships, expansions

  • Product portfolio and pricing strategies

• ✅ Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• ✅ Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• ✅ Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• ✅ Stakeholder Insights

  • Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global Insufflator Market?

-> Global Insufflator market was valued at USD 301 million in 2025 and is projected to reach USD 504 million by 2034, growing at a CAGR of 7.6% during the forecast period.

Which key companies operate in Global Insufflator Market?

-> Key players include W.O.M, Stryker, Karl Storz, Richard Wolf, Olympus, B.Braun, Hoya, STERIS, Fujifilm, Smith & Nephew, Bracco, CONMED, Northgate Technologies, Shiyin Medical, Arthrex, GIMMI GmbH, Hawk, Tonglu Jingrui, Kangyou Medical.

What are the key growth drivers?

-> Key growth drivers include rapid adoption of minimally invasive and robotic‑assisted surgeries, demand for high‑flow intelligent insufflators, hospital infrastructure expansion in emerging Asia‑Pacific markets, and increasing focus on patient safety through gas heating and humidification technologies.

Which region dominates the market?

-> Asia‑Pacific is the fastest‑growing region, driven by large surgical volume and investment in laparoscopic suites, while Europe remains the largest revenue‑generating market due to mature healthcare systems.

What are the emerging trends?

-> Emerging trends include integrated AI‑based pressure feedback, IoT‑enabled remote monitoring, advanced gas heating & humidification modules, and modular designs compatible with robotic platforms, all aimed at reducing postoperative pain and enhancing surgical efficiency.